Despite its ability to act alone in the tumor cells, RasG12V had a relatively minor effect on pro-malignancy activities in MCF-7 breast tumor cells (measured indirectly in terms of CXCL8 release), as compared to the inflammatory cytokines (Figure 1B). This evidence concerns the gene CXCL8 and breast neoplasm.